Grace Therapeutics announced its 2026 fiscal results and a planned Type A meeting with the FDA following a Complete Response Letter (CRL) for its drug GTx-104, an IV nimodipine formulation for aneurysmal Subarachnoid Hemorrhage (aSAH). The FDA's CRL cited issues in manufacturing and non-clinical data but no clinical deficiencies. Grace aims to address these and resubmit the NDA, supported by positive Phase 3 trial results showing safety and efficacy benefits over oral nimodipine. The company reported a reduced net loss of $7.8 million for fiscal 2026 and expects its cash runway to last at least 12 months while preparing for potential FDA approval and commercialization.
Lululemon invested in Syntetica's $30 million Series A funding to support its innovative recycling of Nylon 6 and Nylon 6,6, materials difficult to separate and reuse in textile waste. This move aligns with growing industry demand for sustainable, co...
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
